HPV vaccine: no increased risk of Guillain-Barré syndrome

2017 ◽  
Vol 1643 (1) ◽  
pp. 7-7
Keyword(s):  
Hpv Vaccine ◽  
Guillain Barre Syndrome ◽  
Increased Risk ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barré syndrome after COVID-19 vaccination

2021 ◽  
Vol 14 (7) ◽  
pp. e244125
Author(s):  
Norma McKean ◽  
Charmaine Chircop
Keyword(s):  
Characteristic Feature ◽  
Temporal Correlation ◽  
Guillain Barre Syndrome ◽  
Initial Symptom ◽  
Increased Risk ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

We report a case of Guillain-Barré syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca). Thus far, there has been no evidence of an increased risk of GBS resulting from either COVID-19 infection nor from COVID-19 vaccines; however, individual cases and population cohorts should be scrutinised, in order to ensure the constant evaluation of such risks. It is as yet not possible to draw conclusions about any significant association between COVID-19 vaccination and GBS. A temporal correlation does not imply, and should not be deemed to signify, causality. However, it is important to remain vigilant, so that any potential increased risk is properly evaluated. The specific presentation of bifacial weakness as the initial symptom may be a characteristic feature of GBS in the context of recent COVID-19 vaccination.

Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine

2017 ◽  
Vol 17 (1) ◽  
pp. 99-102 ◽  
Author(s):  
Geneviève Deceuninck ◽  
Chantal Sauvageau ◽  
Vladimir Gilca ◽  
Nicole Boulianne ◽  
Gaston De Serres
Keyword(s):  
Hpv Vaccine ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals GUILLAIN-BARRÉ SYNDROME

2018 ◽  
Vol 25 (04) ◽  
pp. 538-544
Author(s):  
Muhammad Ahmed Zia ◽  
Yasser Masood ◽  
Muhammad Kashif Salman
Keyword(s):  
Case Series ◽  
Guillain Barre Syndrome ◽  
P Value ◽  
Female Ratio ◽  
Autonomic Disturbance ◽  
Case Series Study ◽  
Increased Risk ◽  
Guillain Barré Syndrome ◽  
Autonomic Instability ◽  
Guillain Barré

Objectives: To determine the outcome of autonomic disturbances in childrenwith Guillain Barre Syndrome. Study Design: Case series study. Setting: Pediatric ICU andNeurology ward of Nishtar Medical University/hospital Multan. Period: 9th June 2014 to 8th June2015. Methods: 48 children having age less than 18 years. Clinical examination of centralnervous system was conducted by single examiner to see presence of acute flaccid paralysisand to detect autonomic dysfunction. Cerebrospinal fluid analysis for albumino-cytologicdissociation, electromyography and nerve conduction studies was done in every patient ofGuillain Barre Syndrome. Outcome was noted as expired, discharged or LAMA. Results: Meanage was 5.4 years and male female ratio was 1.2:1. Total 34 children were found to have clinicalevidence of autonomic instability. Among 48 children, 17 children (35.4%) received no therapy,28 children (58.3%) received Intravenous immunoglobulin (IVIG) therapy, and 3 children (6.3%)received plasmapheresis. In children with autonomic disturbance, 24 children (70.6%) weredischarged, 8 children (23.5%) expired and 2 children (5.9%) LAMA. Of the total 14 childrenwithout autonomic disturbance, 11 children (78.6%) were discharged, 3 children (21.4%)expired and no child LAMA (p-value >0.05). Mean duration of stay for patients with autonomicinstability was 130 days versus 63 days in patients without autonomic instability (p-value<0.005). Demyelination variety was seen in 35 children (72.9%) and axonal degenerationin 13 children (27.1%). Mortality was high in children who had axonal degeneration but withinsignificant p-value of >0.05. Conclusions: Autonomic instability is common in patients ofGBS and is associated with increased risk of morbidity. Prompt recognition and treatment ofautonomic instability can improve the outcomes of children with GBS.

scholarly journals Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018–2019 Season

2020 ◽  
Author(s):  
Silvia Perez-Vilar ◽  
Mao Hu ◽  
Eric Weintraub ◽  
Deepa Arya ◽  
Bradley Lufkin ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Vaccine Safety ◽  
The United States ◽  
Guillain Barre Syndrome ◽  
High Dose ◽  
Medicare Beneficiaries ◽  
Increased Risk ◽  
Guillain Barré Syndrome ◽  
Control Window ◽  
Guillain Barré

Abstract Background The Vaccine Safety Datalink (VSD) identified a statistical signal for an increased risk of Guillain-Barré syndrome (GBS) in days 1–42 after 2018–2019 high-dose influenza vaccine (IIV3-HD) administration. We evaluated the signal using Medicare. Methods We conducted early- and end-of-season claims-based self-controlled risk interval analyses among Medicare beneficiaries ages ≥65 years, using days 8–21 and 1–42 postvaccination as risk windows and days 43–84 as control window. The VSD conducted chart-confirmed analyses. Results Among 7 453 690 IIV3-HD vaccinations, we did not detect a statistically significant increased GBS risk for either the 8- to 21-day (odds ratio [OR], 1.85; 95% confidence interval [CI], 0.99–3.44) or 1- to 42-day (OR, 1.31; 95% CI, 0.78–2.18) risk windows. The findings from the end-of-season analyses were fully consistent with the early-season analyses for both the 8- to 21-day (OR, 1.64; 95% CI, 0.92–2.91) and 1- to 42-day (OR, 1.12; 95% CI, 0.70–1.79) risk windows. The VSD’s chart-confirmed analysis, involving 646 996 IIV3-HD vaccinations, with 1 case each in the risk and control windows, yielded a relative risk of 1.00 (95% CI, 0.06–15.99). Conclusions The Medicare analyses did not exclude an association between IIV3-HD and GBS, but it determined that, if such a risk existed, it was similar in magnitude to prior seasons. Chart-confirmed VSD results did not confirm an increased risk of GBS.

scholarly journals COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications

2020 ◽  
Vol 2 (12) ◽  
pp. 2702-2714
Author(s):  
Mayanja M. Kajumba ◽  
Brad J. Kolls ◽  
Deborah C. Koltai ◽  
Mark Kaddumukasa ◽  
Martin Kaddumukasa ◽  
...  
Keyword(s):  
Neurological Complications ◽  
Guillain Barre Syndrome ◽  
Increased Risk ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Symptom Overlap

scholarly journals Is an Increased Risk of Developing Guillain–Barré Syndrome Associated with Seasonal Influenza Vaccination? A Systematic Review and Meta-Analysis

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 150 ◽  
Author(s):  
Marek Petráš ◽  
Ivana Králová Lesná ◽  
Jana Dáňová ◽  
Alexander M. Čelko
Keyword(s):  
Systematic Review ◽  
Influenza Vaccination ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Guillain Barre Syndrome ◽  
Increased Risk ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

While the weight of epidemiological evidence does not support a causal link with influenza vaccination evaluated over the last 30 years, Guillain–Barré syndrome (GBS) has been considered a vaccine-associated adverse event of interest since 1976. To investigate the existence of GBS risk after vaccination against seasonal influenza, a systematic review and meta-analysis have been conducted based on 22 eligible epidemiological studies from 1981 to 2019 reporting 26 effect sizes (ESs) in different influenza seasons. The primary result of our meta-analysis pointed to no risk of vaccine-associated GBS, as documented by a pooled ES of 1.15 (95% CI: 0.97–1.35). Conversely, an obvious high risk of GBS was observed in patients with previous influenza-like illness (ILI), as demonstrated by a pooled ES of 9.6 (95% CI: 4.0–23.0) resulting from a supplementary analysis. While the meta-analysis did not confirm the putative risk of vaccine-associated GBS suggested by many epidemiological studies, vaccination against seasonal influenza reduced the risk of developing ILI-associated GBS by about 88%. However, to obtain strong evidence, more epidemiological studies are warranted to establish a possible coincidence between vaccination and ILI prior to GBS onset.

scholarly journals FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barré syndrome

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0192703 ◽  
Author(s):  
Zhahirul Islam ◽  
Israt Jahan ◽  
Rijwan U. Ahammad ◽  
Mohammad Shahnaij ◽  
Shamsun Nahar ◽  
...  
Keyword(s):  
Nerve Damage ◽  
Guillain Barre Syndrome ◽  
Promoter Polymorphisms ◽  
Increased Risk ◽  
Guillain Barré Syndrome ◽  
Sfas Level ◽  
Guillain Barré
Sign in / Sign up

Export Citation Format

Share Document